Given that loss-of-function polymorphism of Ddah1 promoter was associated with increased susceptibility to metabolic syndrome (MS)13, we asked whether ADMA level and Ddah1 promoter polymorphism were associated with the bone mineral density (BMD) in humans. The gene discussed is DDAH1; the disease is myeloid sarcoma.